Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Straumann Holding AGXSWX:STMN -0.99%96 Equity-to-Asset is 0.58 as of Dec. 2025, which is 2% above its 10-year median of 0.57. GuruFocus rates XSWX:STMN with a GF Score™ of 96/100 and a GF Value™ of CHF137.56 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Straumann Holding AG ranks worse than 58.43% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Straumann Holding AG's Total Stockholders Equity for the quarter that ended in Dec. 2025 was CHF2,161 Mil. Straumann Holding AG's Total Assets for the quarter that ended in Dec. 2025 was CHF3,758 Mil.
Therefore, Straumann Holding AG's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.58.
The historical rank and industry rank for Straumann Holding AG's Equity-to-Asset or its related term are showing as below:
XSWX:STMN'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47 Med: 0.57 Max: 0.64
Current: 0.58
During the past 13 years, the highest Equity to Asset Ratio of Straumann Holding AG was 0.64. The lowest was 0.47. And the median was 0.57.
XSWX:STMN's Equity-to-Asset is ranked worse than 58.43% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs XSWX:STMN: 0.58
Straumann Holding AG (XSWX:STMN) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Straumann Holding AG Equity-to-Asset Related Terms
Straumann Holding AG Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Straumann Holding AG's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:STMN vs ISRG, BDX, MDLN: Equity-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Straumann Holding AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Straumann Holding AG (XSWX:STMN) has a Equity-to-Asset of 0.58 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Straumann Holding AG and its competitors. This is near median its historical median of 0.57. Over the past decade, Straumann Holding AG's Equity-to-Asset has ranged from 0.47 to 0.64. According to the industry distribution chart, Straumann Holding AG ranks #499 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 58.4%.
Is Straumann Holding AG's Equity-to-Asset too high?
Straumann Holding AG's current Equity-to-Asset of 0.58 is near median its 10-year median of 0.57. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 0.64. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Straumann Holding AG's value of 0.58 is 10.8% below this industry median. Based on the distribution chart, Straumann Holding AG ranks #499 out of 854 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Straumann Holding AG has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's Equity-to-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #499 out of 854 companies for Equity-to-Asset. This places Straumann Holding AG in the lower half of its industry. The industry median Equity-to-Asset is 0.65. Straumann Holding AG's value of 0.58 is 10.8% below this benchmark. Historically, Straumann Holding AG's own Equity-to-Asset has ranged from 0.47 to 0.64 over the past decade. While the company's 10-year median is 0.57 vs. the industry median of 0.65, Straumann Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Straumann Holding AG's current Equity-to-Asset of 0.58 is 10.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Straumann Holding AG and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current Equity-to-Asset is 0.58, which is near median its own 10-year median of 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Straumann Holding AG (XSWX:STMN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF137.56, compared to a current price of CHF99.16 — trading 27.9% below its estimated fair value. The current Equity-to-Asset is 0.58, which is near median its 10-year median of 0.57 and 10.8% below the Medical Devices & Instruments industry median of 0.65. Straumann Holding AG's overall GF Score™ is 96/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Straumann Holding AG (XSWX:STMN), the current Equity-to-Asset is 0.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (XSWX:STMN) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of CHF99.16 is trading 27.9% below its estimated GF Value™ of CHF137.56.
GuruFocus considers Straumann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:STMN:
Equity-to-Asset: 0.58 (near median its 10-year median of 0.57)
GF Value™: CHF137.56 vs. price of CHF99.16 (27.9% below fair value)
Industry Position: 10.8% below the Medical Devices & Instruments median (#499 of 854)
No single metric tells the full story. See the XSWX:STMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
96GF Score
Get the complete analysis for XSWX:STMN
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:STMN has been successfully added to your 
